Valuation: Opus Genetics, Inc.

Market Cap 241M 212M 197M 181M 340M 23.22B 345M 2.34B 914M 11.41B 905M 886M 39.47B P/E 2026 *
-2.72x
P/E 2027 * -3.85x
Enterprise Value 241M 212M 197M 181M 340M 23.22B 345M 2.34B 914M 11.41B 905M 886M 39.47B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 16.3x
Free-Float
88.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+4.11%
1 week-6.88%
Current month-25.91%
1 month-17.92%
3 months-41.78%
6 months+8.36%
Current year+51.49%
1 week 2.82
Extreme 2.82
3.37
1 month 2.82
Extreme 2.82
4.39
Current year 1.88
Extreme 1.88
5.81
1 year 1.04
Extreme 1.04
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 52 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap.
5/18/26
The Foundation Fighting Blindness, Inc.
SellCompany -1,700,000 2.0886%
4/23/26 Sell

Chief Financial Officer

7,842 0.0110%
4/23/26 Sell

Chief Technology Officer

7,542 0.0106%
Change 5-day change 1-year change 3-year change Capi.($)
+4.11%-6.88%+151.65%-22.52% 241M
+0.67%+1.21%+48.16%+159.80% 1,057B
+1.64%+4.03%+55.24%+53.86% 624B
+0.92%+1.84%+35.81%+81.01% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.41%+2.99%+22.26%+60.23% 201B
-0.62%-3.08%+14.96%+67.58% 162B
Average +0.95%-0.40%+38.56%+44.54% 361.42B
Weighted average by Cap. +0.75%+1.57%+35.67%+77.48%

Financials

2026 *2027 *
Net sales 15.18M 13.33M 12.4M 11.38M 21.38M 1.46B 21.71M 147M 57.53M 719M 56.99M 55.76M 2.49B 14.83M 13.03M 12.11M 11.12M 20.89M 1.43B 21.21M 144M 56.2M 702M 55.68M 54.48M 2.43B
Net income -94.49M -82.99M -77.18M -70.82M -133M -9.1B -135M -916M -358M -4.47B -355M -347M -15.47B -67.77M -59.52M -55.35M -50.79M -95.44M -6.53B -96.91M -657M -257M -3.21B -254M -249M -11.09B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-07-24 US$3.049 +4.42% 912,940
26-07-23 US$2.920 -4.26% 1,453,407
26-07-22 US$3.050 -0.33% 555,525
26-07-21 US$3.060 +0.33% 971,010
26-07-20 US$3.050 -6.73% 1,210,488
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2.920USD
Average target price
10.56USD
Spread / Average Target
+261.49%

Quarterly revenue - Rate of surprise